Clinical Trial Update: Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)

View source ↗

Summary

A completed pharmacogenetic trial and long-term follow-up of the PRISMS trial in multiple sclerosis. The study was sponsored by Merck KGaA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Status: COMPLETED